Skip to main content

Dr. Wilbur Chen, Nationally-Recognized Vaccine Researcher, Selected for Federal Committee that Guides Immunization Policies

January 27, 2021

Wilbur H. Chen, MD, MS, FIDSA, FACP

He Will Serve Four-Year Term on Advisory Committee that Sets Recommendations for COVID-19 Vaccines and Other Immunization Practices

Wilbur H. Chen, MD, MS, FIDSA, FACP, Professor of Medicine at the University of Maryland School of Medicine (UMSOM), has been named a new voting member of the federal government’s Advisory Committee on Immunization Practices (ACIP), the prestigious board of experts that makes recommendations on the safe use of vaccines for Americans. The U.S. Department of Health and Human Services selected Dr. Chen for the 15-member advisory committee based on his expertise and national leadership in vaccinology, infectious diseases, public health, and preventive medicine. He will remain in his current role at UMSOM while he serves in his four-year term, which began last month.

David Marcozzi, MDAn internist and infectious disease physician-scientist with expertise in vaccinology, Dr. Chen has been instrumental in setting important policies to help the State of Maryland manage the COVID-19 pandemic during the past year. Last March, Maryland Governor Larry Hogan appointed Dr. Chen, along with David Marcozzi, MD, Professor and Associate Chair of Population Health, UMSOM Department of Emergency Medicine, and University of Maryland Medical System (UMMS) COVID-19 Incident Commander, to be members of the state’s Coronavirus Response Team. This special panel has been advising the Governor and top administration officials on important health and emergency management decisions relating to management of the pandemic and vaccine distribution.

E. Albert Reece, MD, PhD, MBADr. Chen is a top national leader in public health issues and vaccine research, who is equally adept in the clinical world of treating and preventing infectious diseases, and in the research and development of innovative new vaccines,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. “I can think of no one more fitting to serve on this important committee which helps set national vaccine policy.”

In addition to his faculty appointment at UMSOM, Dr. Chen is Chief of the Adult Clinical Studies section within the Center for Vaccine Development and Global Health and Director of the Institution's Travel Medicine Practice. His research has been devoted to developing vaccines for enteric pathogens, infectious diseases chiefly of resource-poor and economically disadvantaged countries and populations. He also has worked to developed improved vaccines for the elderly, a rapidly growing segment of the global population, which is susceptible to many infections and a special population that generally responds poorly to vaccination.

Kathleen Neuzil, MD MPH, FIDSA“Dr. Chen will be an incredible asset to this important committee, bringing his gifted skills as a vaccine researcher, public health expert, and clinician,” said Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD Distinguished Professor in Vaccinology and Director of CVD. “I have no doubt that the passion, intellect, and energy that he brings to all of his work will enable him to excel in this new role.”

The Centers for Disease Control and Prevention (CDC) sets the U.S. adult and childhood immunization schedules based on recommendations from the Advisory Committee on Immunization Practices (ACIP). Before recommending any vaccine, ACIP considers many factors, including the safety, effectiveness, and effect on health equity of each vaccine. The Committee is currently holding numerous emergency meetings to address COVID-19 vaccines. Under normal circumstances, there are three scheduled public full-committee meetings per year that vote on the recommendations for all U.S. approved vaccines. Meanwhile, the ACIP also conducts biweekly vaccine-specific workgroup meetings. These are held to review and assess the evidence for immunizations, which determine the proposed recommendations for the ACIP.

“I am incredibly honored to serve in this capacity and grateful for this opportunity to take on this vital public health role during one of the most challenging public health crises of the previous century,” said Dr. Chen.

Dr. Chen is an active investigator for two funded NIAID-supported vaccine networks housed at CVD – a Vaccine and Treatment Evaluation Unit (VTEU) and a Collaborative Influenza Vaccine Innovation Center (CIVICs) Clinic Core. He was the principal investigator of the NIAID-supported Food and Waterborne Diseases Integrated Research Network Clinical Research Unit. He has been a principal investigator on vaccine trials for influenza viruses, bioterror agents, and intestinal microbes including typhoid, cholera, and life-threatening strains of E. coli. He has been at the UMSOM for nearly two decades and did his residency in internal medicine at the Johns Hopkins University Bayview Medical Center. He received his M.D. from Howard University College of Medicine and his B.A. at Boston University.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding.  As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies.  In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools.  The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Thursday, September 16, 2021

    First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever

    A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV.


    Tuesday, January 05, 2021

    Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine

    Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.


    Tuesday, January 05, 2021

    University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate

    Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.


    Tuesday, May 05, 2020

    UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19

    In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.


    Tuesday, December 10, 2019

    UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water

    Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.


    Tuesday, March 20, 2018

    UMSOM Vaccine Experts Lead Trial on Avian Flu Vaccine

    Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China.


    Friday, February 23, 2018

    University of Maryland School of Medicine Vaccine Expert Highlights Need for Vaccination Among Older Adults During Capitol Hill Briefing

    Today at a briefing on Capitol Hill, Wilbur Chen, MD, MS, Associate Professor of Medicine at the University of Maryland School of Medicine, warned that the U.S. population of adults 65 and older is expected to rise significantly over the next few decades, making vaccinations against diseases like influenza, pneumonia and shingles for this population very critical.


    Monday, May 15, 2017

    UM SOM Vaccine Researcher Receives Top Award in the Study of Infectious Diseases

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease at UM SOM, has been awarded the Maxwell Finland Award for Scientific Achievement by the National Foundation for Infectious Diseases (NFID). The award honors his extensive accomplishments in public health; over his career, he has identified solutions to major sources of disease in the developing world, including cholera, typhoid, and Shigella dysentery. The award will be presented on Thursday, May 18, 2017 at the Hyatt Regency Bethesda in Bethesda, Md.


    Friday, June 10, 2016

    FDA Approves Vaccine for Cholera Invented and Developed at University of Maryland School of Medicine

    In a milestone that was years in the making, a vaccine to prevent cholera, invented and developed by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development, was approved today by the U.S. Food and Drug Administration (FDA).